Adicet Bio Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...

Prasinezumab continues to be well tolerated and no new safety signals were observed.

Will support clinical development of Nirsum’s lead development candidate, NRS-033.

Dr. Marc Damelin possesses extensive industry experience in oncology drug discovery and development across a variety of ...

Evidence of efficacy and safety data support the potential for vatiquinone to fill the significant unmet need for patients ...

Great Bay Bio (GBB) announced today the first close of its Series B financing round, led by a strategic investment ...

The acquisition is expected to be completed in the coming days.

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Biomedicines as part of its efforts to drive growth and innovation in the biopharmaceutical sector. Established in 2021 and ...

Demonstrates its commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve.

In anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, BioVaxys ...

With a total area exceeding 16,000 square meters, the new facility houses the company's production, quality, data, and ...